Market open
Alkermes/$ALKS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Alkermes
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Ticker
$ALKS
Sector
Trading on
Industry
Biotechnology
Headquarters
Dublin, Ireland
Employees
1,800
Website
Alkermes Metrics
BasicAdvanced
$5.7B
16.03
$2.17
0.46
-
Price and volume
Market cap
$5.7B
Beta
0.46
52-week high
$36.45
52-week low
$22.90
Average daily volume
1.8M
Financial strength
Current ratio
3.042
Quick ratio
2.453
Long term debt to equity
4.735
Total debt to equity
5.156
Interest coverage (TTM)
18.63%
Management effectiveness
Return on assets (TTM)
12.54%
Return on equity (TTM)
27.90%
Valuation
Price to earnings (TTM)
16.034
Price to revenue (TTM)
3.695
Price to book
3.85
Price to tangible book (TTM)
4.09
Price to free cash flow (TTM)
14.187
Growth
Revenue change (TTM)
-6.36%
Earnings per share change (TTM)
3.47%
3-year revenue growth (CAGR)
9.89%
3-year earnings per share growth (CAGR)
94.24%
What the Analysts think about Alkermes
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Alkermes stock.
Alkermes Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Alkermes Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Alkermes News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Alkermes stock?
Alkermes (ALKS) has a market cap of $5.7B as of February 27, 2025.
What is the P/E ratio for Alkermes stock?
The price to earnings (P/E) ratio for Alkermes (ALKS) stock is 16.03 as of February 27, 2025.
Does Alkermes stock pay dividends?
No, Alkermes (ALKS) stock does not pay dividends to its shareholders as of February 27, 2025.
When is the next Alkermes dividend payment date?
Alkermes (ALKS) stock does not pay dividends to its shareholders.
What is the beta indicator for Alkermes?
Alkermes (ALKS) has a beta rating of 0.46. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.